ABOT 1HCY26 profit rises 17%

August 28, 2026 (MLN): Abbott Laboratories (Pakistan) Limited (PSX: ABOT) reported a 17% increase in its net profit for the half-year ended June 30, 2026 (1HCY26), reaching Rs4.14bn compared to Rs3.54bn in the corresponding period last year.

Reflecting this solid bottom-line growth, basic and diluted earnings per share (EPS) for the six-month period improved to Rs42.29, up from Rs36.19 in 1HCY25.

The primary catalyst behind the financial expansion was a combination of steady local revenue growth and expanded gross margins.

Net sales grew by 4% year-on-year to Rs38.03bn, up from Rs36.41bn in 1HCY25, as a 6% increase in local sales (Rs37.15bn) offset a 41% decline in export sales (Rs875.69m).

Meanwhile, the cost of sales decreased slightly by 1% to Rs23.58bn, enabling gross profit to expand 15% to Rs14.45bn compared to Rs12.61bn in the prior year.

On the operational front, overheads expanded to support distribution and administration.

Selling and distribution expenses rose 11% to Rs6.15bn, administrative expenses grew 22% to Rs776.09m, and other charges increased 7% to Rs887.41m.

Supported by a 43% boost in "other income", operating profit before finance costs rose 20% to Rs7.24bn.

Below the operating line, finance costs remained minimal, dropping 5% to Rs35.64m. Although the company absorbed a minimum tax differential levy of Rs159.45m, profit before taxation grew by 17% to reach Rs7.04bn.

The company absorbed an 18% higher net income tax expense of Rs2.90bn for the six-month period.

Supported by local top-line strength, gross margin expansion, and higher secondary income, Abbott Laboratories (Pakistan) Limited securely closed the half-year with its net profit reaching Rs4.14bn.

Copyright Mettis Link News